TY - JOUR
T1 - The importance of non-coding RNAs in neurodegenerative processes of diabetes-related molecular pathways
AU - Jarosz-Popek, Joanna
AU - Wolska, Marta
AU - Gasecka, Aleksandra
AU - Czajka, Pamela
AU - Jakubik, Daniel
AU - Sharif, Lucia
AU - Adem, Taqwa
AU - Liu, Wei-Ling
AU - Mirowska-Guzel, Dagmara
AU - Postula, Marek
AU - Eyileten, Ceren
N1 - Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Diabetes mellitus (DM) is a complex condition and serious health problem, with growing occurrence of DM-associated complications occurring globally. Persistent hyperglycemia is confirmed as promoting neurovascular dysfunction leading to irreversible endothelial cell dysfunction, increased neuronal cell apoptosis, oxidative stress and inflammation. These collaboratively and individually result in micro-and macroangiopathy as well as neuropathy demonstrated by progressive neuronal loss. Recently, major efforts have been pursued to select not only useful diagnostic and prognostic biomarkers, but also novel therapeutic approaches. Both microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) belong to a class of non-coding RNAs identified in most of the body fluids i.e., peripheral blood, cerebrospinal fluid, brain tissue and neurons. Numerous miRNAs, lncRNAs and their target genes are able to modulate signaling pathways known to play a role in the pathophysiology of progressive neuronal dysfunction. Therefore, they pose as promising biomarkers and treatment for the vast majority of neurodegenerative disorders. This review provides an overall assessment of both miRNAs’ and lncRNAs’ utility in decelerating progressive nervous system impairment, including neurodegeneration in diabetic pathways.
AB - Diabetes mellitus (DM) is a complex condition and serious health problem, with growing occurrence of DM-associated complications occurring globally. Persistent hyperglycemia is confirmed as promoting neurovascular dysfunction leading to irreversible endothelial cell dysfunction, increased neuronal cell apoptosis, oxidative stress and inflammation. These collaboratively and individually result in micro-and macroangiopathy as well as neuropathy demonstrated by progressive neuronal loss. Recently, major efforts have been pursued to select not only useful diagnostic and prognostic biomarkers, but also novel therapeutic approaches. Both microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) belong to a class of non-coding RNAs identified in most of the body fluids i.e., peripheral blood, cerebrospinal fluid, brain tissue and neurons. Numerous miRNAs, lncRNAs and their target genes are able to modulate signaling pathways known to play a role in the pathophysiology of progressive neuronal dysfunction. Therefore, they pose as promising biomarkers and treatment for the vast majority of neurodegenerative disorders. This review provides an overall assessment of both miRNAs’ and lncRNAs’ utility in decelerating progressive nervous system impairment, including neurodegeneration in diabetic pathways.
KW - Biomarker
KW - LncRNA
KW - MiR
KW - MiRNA
KW - Non-coding RNA
KW - Novel biomarker
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85101846277&partnerID=8YFLogxK
U2 - https://doi.org/10.3390/jcm10010009
DO - https://doi.org/10.3390/jcm10010009
M3 - Review article
C2 - 33374507
SN - 2077-0383
VL - 10
SP - 1
EP - 23
JO - Journal of clinical medicine
JF - Journal of clinical medicine
IS - 1
M1 - 9
ER -